Knowledge graph · Trial
Intermittent Fasting (IF) Has Gained Recognition as a Promising Weight Loss Approach That Improves Body Weight, Insulin Resistance, and Metabolism. While Standard Diets Are Common in PCOS Management, IF May Address the Underlying Causes of Weight Gain and Offer Additional Metabolic Benefits
COMPLETED
- Identifier
- CI-TRIAL-00085358
- Entity page
- /trial/NCT06804044 ↗
- Edges
- 0
- Neighbours
- none
- Drawn
- 0 of 0 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Data not yet available
No knowledge edge or registry link touches this trial on this environment. Edges appear once a source (CIViC, ChEMBL, openFDA, ClinicalTrials.gov, GDC) states one — CancerIndex does not infer them.
What CancerIndex knows
- Open Intermittent Fasting (IF) Has Gained Recognition as a Promising Weight Loss Approach That Improves Body Weight, Insulin Resistance, and Metabolism. While Standard Diets Are Common in PCOS Management, IF May Address the Underlying Causes of Weight Gain and Offer Additional Metabolic Benefits
- Lung Non-Small Cell Carcinoma
- Malignant Colorectal Neoplasm
- ABL1
- EGFR